HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Too Faced To Appeal NAD Ruling On '1,944% More Volume' Mascara Claim

This article was originally published in The Rose Sheet

Executive Summary

The National Advertising Division sides with challenger Benefit Cosmetics, advising Lauder's Too Faced brand to discontinue claims that its Better Than Sex mascara awards “1,944% more volume." Too Faced is appealing the decision, which raises questions about evidentiary thresholds and confidentiality protections.

You may also be interested in...



Health, Beauty And Wellness News: Revlon CEO, Rodan + Fields Investment

Too Faced fails in appeal of NAD findings; more of same in supplement GMP warnings; vitamin D benefit for in vitro fertilization shown; TropicSport promotes mineral over chemical sunscreens; Rodan + Fields investment by TPG; and Revlon chairman's daughter takes the helm.

NAD Head Laura Brett On Program Streamlining, Class Action Climate And Mascara Feuds

A Q&A with Laura Brett, four months into her new role as director of the National Advertising Division.

Benefit's '#1 Best-Selling' Mascara Claims Are Outdated, Misleading – NAD

NAD acknowledges that asterisked disclosures limit Benefit's best-selling claims for They're Real! Lengthening Mascara to specific timeframes more than a year ago. However, the main message of the advertiser's claims deceptively conveys that its mascara is currently the prestige category leader, NAD says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel